Cariprazine + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Jul 7, 2022 → Oct 4, 2024
NCT ID
NCT05439616About Cariprazine + Placebo
Cariprazine + Placebo is a phase 3 stage product being developed by AbbVie for Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT05439616. Target conditions include Autism Spectrum Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05368558 | Phase 3 | Terminated |
| NCT05384483 | Approved | Completed |
| NCT05439616 | Phase 3 | Completed |
| NCT04777357 | Phase 3 | Recruiting |
| NCT03738215 | Phase 3 | Completed |
| NCT03593213 | Phase 3 | Terminated |
| NCT03573297 | Phase 3 | Completed |
Competing Products
20 competing products in Autism Spectrum Disorder